Abstract
Objective: The objective of the present study is to confirm and/or prove the beneficial outcomes from using Brewer’s yeast and Ginger in constipation-predominant irritable bowel syndrome (IBS-C) subjects compared to placebo.
 Methods: A total of 45 patients suffering from IBS-C were enrolled in a double-blind placebo-controlled study as defined by Rome III criteria. Parallel groups were randomly assigned in this study: A placebo group, Brewer’s yeast group, and ginger group, taken daily for 20 days. IBS severity scale and visual analog scale for IBS (VAS-IBS) were used to assess the severity of pain, abdominal distention, and constipation (IBS-C) subjects. The data were measured at 3 times: At 0 time (T0), after 10 days of treatment (T10), and after 20 days of treatment (T20) for the three treatment groups.
 Results: Intragroup analysis showed a clinically significant reduction in the symptoms of abdominal pain, distention, and constipation, in the Brewer’s yeast group compared to placebo after the 20 days of the study. There was also a significant reduction of abdominal distention and constipation symptoms in the ginger group throughout the study.
 Conclusion: This study reveals the beneficial effects of Brewer’s yeast and ginger in reducing troublesome gastrointestinal symptoms in subjects with IBS-C and holds the promise to use them in IBS-C patient.
Highlights
Irritable bowel syndrome (IBS) is a widespread gastrointestinal disorder with symptoms of abdominal pain, discomfort, cramping, and alternating bowel habits of constipation and diarrhea [1]
This study concentrates on constipation-predominant IBS-C, which can be defined as constipation associated with abdominal pain and discomfort that is generally relieved by defecation [7], affects about 34% of the IBS population [8,9]
A total of 45 subjects with IBS-C were included into this study and were successfully randomized to be either in placebo group (n=15) or active treatment groups: Brewer’s yeast (n=15) and ginger group (n=15)
Summary
Irritable bowel syndrome (IBS) is a widespread gastrointestinal disorder with symptoms of abdominal pain, discomfort, cramping, and alternating bowel habits of constipation and diarrhea [1]. The treatment mainly concentrates on the relief of symptoms to have a normal quality of life [3]. It can be classified into three specific forms: Constipation-predominant IBS-C, diarrhea-predominant IBS-D, or mixed symptoms of constipation and diarrhea (IBS-M) [4]. This study concentrates on constipation-predominant IBS-C, which can be defined as constipation associated with abdominal pain and discomfort that is generally relieved by defecation [7], affects about 34% of the IBS population [8,9]. There is no drug therapy that can be used safely and chronically to treat all of the symptoms of IBS-C and improves the patient’s health-related quality of life [14]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Asian Journal of Pharmaceutical and Clinical Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
